Y-mAbs Therapeutics, Inc.

Historical 13F Holders

Symbol
YMAB
CUSIP
984241109
All holders as of
Q3 2025
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 984241109 since 12/18/2024, largest first.

Filer % of Class Filed
Acorn Bioventures, L.P. 13G/A
6.2% 8/20/2025
Event 8/19/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
Beryl Capital Management LLC 13G/A
0% 11/14/2025
Event 9/30/2025
Caligan Partners LP 13G/A
0% 11/14/2025
Event 9/30/2025
Glazer Capital, LLC 13G/A
0% 11/13/2025
Event 9/30/2025
HBM Healthcare Investments (Cayman) Ltd. 13G/A 0% 11/14/2025
Event 9/30/2025
Paradigm Biocapital Advisors LP 13G/A
0% 11/14/2025
Event 9/30/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q3 2 16.4 k $78.3 k
2025 Q2 100 28.4 M $128 M
2025 Q1 108 28.8 M $128 M
2024 Q4 118 31.7 M $248 M
2024 Q3 111 25.8 M $339 M
2024 Q2 103 24.6 M $297 M
2024 Q1 105 23.4 M $381 M
2023 Q4 100 20.9 M $143 M
2023 Q3 102 19.8 M $108 M
2023 Q2 100 19.5 M $132 M
2023 Q1 92 19.3 M $96.9 M
2022 Q4 96 20.2 M $98.5 M
2022 Q3 105 23.6 M $340 M
2022 Q2 97 24.8 M $375 M
2022 Q1 93 25.3 M $301 M
2021 Q4 100 25.8 M $419 M
2021 Q3 100 26.2 M $749 M
2021 Q2 104 26.1 M $887 M
2021 Q1 120 26.5 M $805 M
2020 Q4 119 22.8 M $1.13 B
2020 Q3 109 21.4 M $823 M
2020 Q2 112 21.5 M $928 M
2020 Q1 83 20.3 M $529 M
2019 Q4 84 19.9 M $622 M
2019 Q3 68 13.3 M $347 M
2019 Q2 61 11.1 M $254 M
2019 Q1 47 8.48 M $222 M
2018 Q4 44 8.76 M $177 M
2018 Q3 40 7.75 M $206 M